See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
News|Videos|November 3, 2026
Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma
Author(s)Hong Jae Chon, MD, PhD
Rapid readout: BGB-233 shows strong responses and good safety in heavily pretreated liver cancer, with 36% ORR at 450 mg and Phase 3 planned.
Advertisement
Hong Jae Chon, MD, PhD, of CHA Bundang Medical Center in Seongnam, South Korea, reviews updated dose escalation data and the first disclosure of randomized dose optimization results from the phase 1 study of BGB-B2033, a GPC3 x 4-1BB bispecific antibody, in patients with previously treated advanced hepatocellular carcinoma, as presented at the 2026 ESMO Congress.
Advertisement
Related to this article
Community hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Roswell Park researchers identified a promising strategy to overcome resistance to KRAS-targeted cancer therapies.
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer
2
Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma
3
Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC
4
Cross Currents: Dual EGFR/MET Inhibition in EGFR-Mutated NSCLC
5